News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
Enrollment Completed Four Months Ahead of Schedule; Two Interim Data Analyses On Track for 2019 MONTREAL , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other
View HTML
Toggle Summary Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates
Patient Enrollment in Phase 3 MOVE Trial of Palovarotene for FOP On Track; Two Interim Data Analyses Expected in 2019 MONTREAL , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with
View HTML
Toggle Summary Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer
MONTREAL , July 13, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the appointment of experienced finance executive, Steve Forte
View HTML
Toggle Summary Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors
Accomplished Biopharma Leader Brings Over 30 Years of Experience Leading Strategic and Commercial Efforts MONTREAL , July 05, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone
View HTML
Toggle Summary Clementia to Present at the Jefferies 2018 Global Healthcare Conference
MONTREAL , May 31, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins , Ph.D., chief executive officer and
View HTML
Toggle Summary Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
Statistically Significant 91% Reduction of New HO at Flare-up Sites at 12 Weeks; 65% Reduction of New HO at 12-Month WBCT Scan Evaluable Patients with No New Bone at 12 Weeks Had No New Bone at 12 Months Company to Host Conference Call Today at 8:30 a.m.
View HTML
Toggle Summary Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates
On Track to Report Data from Part B of its Phase 2 Study of Palovarotene for Fibrodysplasia Ossificans Progressiva This Quarter Enrollment in Phase 3 MOVE Trial On Track, Phase 2 MO-Ped Trial Underway MONTREAL , May 09, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc.
View HTML
Toggle Summary Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
Global, Late-stage Trial for Ultra-rare Skeletal Disease with No Approved Treatments MONTREAL , April 20, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases, today
View HTML
Toggle Summary Clementia to Present at the Cowen and Company 38th Annual Health Care Conference
MONTREAL , March 06, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins , Ph.D., chief executive officer
View HTML
Toggle Summary Clementia Reports 2017 Operating Results and Business Highlights
Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP) On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter MONTREAL , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc.
View HTML